ATTR Cardiac Amyloidosis in a Selected Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2039-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896

Amyloidosis Amyloid Amyloid Neuropathies, Familial +4 more

ACTIVE_NOT_RECRUITING

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

NCT06034405

Lumbar Spinal Stenosis Cardiac Amyloidosis ATTR Amyloidosis Wild Type +3 more

RECRUITING

Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)

NCT04828928

Wild-type Amyloid Cardiopathy

COMPLETED NA

Screening for Aortic Aneurysms in Inland Norway

NCT06403423

Abdominal Aortic Aneurysm Erectile Dysfunction Quality of Life

ENROLLING_BY_INVITATION

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

NCT04569903

Transthyretin Amyloidosis

WITHDRAWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Biopsy proven ATTR (v/wt) amyloidosis inpatients operated with CTS will undergo standard guidelines recommended examinations as 99mTcDPD SPECT CT, echocardiography, ECG, Holter, genetic testing (v/wt), and lab testing, and CMRI as indicated. Exclusion of light chain disease will be done.

All patients will be followed at least yearly as indicated by guidelines (ESC), and patients with development of cardiac amyloidosis will get standard treatment in accordance with guidelines and as approved by the Norwegian government. All patients will be followed for 10 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ATTR Amyloidosis Wild Type ATTR Gene Mutation Carpal Tunnel Syndrome Cardiac Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male \> 50 years
* Female \> 60 years
* operated CTS at Ålesund Hospital

Exclusion Criteria

* not consented
* do not speak Norwegian
* secondary cause of CTS as traumatic or rheumatic
* cannot be followed \> 5 years due to other medical conditions
* Cardiac disease at time of operation for CTS

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No